Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick Stiff, Simonetta Viviani, Veronika Bachanova, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham

Blood (2018) 132 (25): 2639–2642.

https://doi.org/10.1182/blood-2018-07-861641

Published: 2018

Journal Articles

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

John Sweetenham, Jan Walewski, MDPhDProf, Auayporn P. Nademanee, MD, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, MD, Andy I Chen, MD PhD, Patrick Stiff, Simonetta Viviani, MD, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanova, MD, Anna Sureda, MD PhD, Dirk Huebner, Emily K Larsen, Naomi N Hunder, Craig H Moskowitz, MD

Blood (2015) 126 (23): 3172.

https://doi.org/10.1182/blood.V126.23.3172.3172

Published: 2015

Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation

Nancy L. Bartlett, Andy I Chen, MD PhD, Kathryn S. Kolibaba, Thierry Lamy, MDPhD, Surai Jones, Jamie Hirata, Jeff P. Sharman, MD

Blood (2015) 126 (23): 2726.

https://doi.org/10.1182/blood.V126.23.2726.2726

Published: 2015

Journal Articles

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Blood (2014) 124 (21): 4457.

https://doi.org/10.1182/blood.V124.21.4457.4457

Published: 2014

Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski

Blood (2014) 124 (21): 673.

https://doi.org/10.1182/blood.V124.21.673.673

Published: 2014

Journal Articles

Consolidative Autologous Stem Cell Transplant for Double Hit Lymphoma

Andy I Chen, MDPhD, Craig Okada, MD PhD, Nate Gay, MD, Phil Reiss, MD, Stephen Spurgeon, MD, Guang Fan, MD PhD, Rita M. Braziel, MD, Richard T. Maziarz, MD

Blood (2014) 124 (21): 3993.

https://doi.org/10.1182/blood.V124.21.3993.3993

Published: 2014

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Ranjana Advani, MD, Andy I. Chen, MD, PhD, Daniel Lebovic, MD, Mark W. Brunvand, MD, Andre Goy, MD, Julie E. Chang, MD, Ephraim Hochberg, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Bruce D. Cheson, M.D.

Blood (2013) 122 (21): 4399.

https://doi.org/10.1182/blood.V122.21.4399.4399

Published: 2013

Journal Articles

Extramedullary Multiple Myeloma Associated With Reduced Overall Survival: A Retrospective Single-Center Study

Ido Barkay, MD, Richard T. Maziarz, MD, Andy I. Chen, MD, PhD, William Dibb, Yiyi Chen, PhD, Emma C. Scott, MD

Blood (2013) 122 (21): 5317.

https://doi.org/10.1182/blood.V122.21.5317.5317

Published: 2013

Journal Articles

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

Blood (2012) 120 (21): 813.

https://doi.org/10.1182/blood.V120.21.813.813

Published: 2012

Journal Articles

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Ranjana Advani, MD, Daniel Lebovic, MD, Mark Brunvand, MD, Andy I. Chen, MD, PhD, Andre Goy, MD, Julie E. Chang, MD, Lauren S Maeda, MD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Bruce D. Cheson, MD

Blood (2012) 120 (21): 59.

https://doi.org/10.1182/blood.V120.21.59.59

Published: 2012

Journal Articles

Prognostic Features, Treatments, and Disease-Specific Mortality Among Patients with Diffuse Large B-Cell Lymphoma Over the Age of 75: A Single-Center Retrospective Analysis

Stephen D. Smith, MD, Craig Okada, MD, PhD, Andy I. Chen, MD, PhD, Stephen E Spurgeon, MD, Guang Fan, MD, PhD, Jennifer B Dunlap, MD, Nicky Leeborg, MD, Rita M. Braziel, MD, Richard T. Maziarz, MD

Blood (2012) 120 (21): 3673.

https://doi.org/10.1182/blood.V120.21.3673.3673

Published: 2012

Journal Articles

Outcomes of 252 Patients with High Risk Multiple Myeloma Treated with Hematopoietic Stem Cell Transplantation: Identification of Risk Factors Associated with Early Relapse, Shortened Progression Free and Overall Survival

Emma C. Scott, MD, Stephen D. Smith, MD, Andy I. Chen, MD, PhD, Nicky Leeborg, MD, Tarunpreet Bains, MD, Alex Stentz, BS, Rachel Frires, BA, William Dibb, James Dibb, Bryon Allen, NPP, Anne Kratz, RN, Racky Daffe, MS, Yiyi Chen, PhD, Richard T. Maziarz, MD

Blood (2012) 120 (21): 3957.

https://doi.org/10.1182/blood.V120.21.3957.3957

Published: 2012

Journal Articles

A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

Stephen Spurgeon, MD, Andy I Chen, MD, PhD, Craig Okada, MD, PhD, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Gundula Palmbach, Bashi Ratterree, RN, Nan Subbiah, Christine Capper, RN, Elliot M Epner, MD, PhD

Blood (2011) 118 (21): 441.

https://doi.org/10.1182/blood.V118.21.441.441

Published: 2011

Journal Articles

Improved Outcome with Busulfan, Melphalan, and Thiotepa Conditioning (BuMelTt) in Autologous Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

Tarunpreet Bains, MD, Andy I Chen, MD, PhD, Andrew Lemieux, BS, Brandon Hayes-Lattin, MD, Jose F. Leis, MD, PhD, Richard T Maziarz, MD

Blood (2011) 118 (21): 3110.

https://doi.org/10.1182/blood.V118.21.3110.3110

Published: 2011

Journal Articles

Long Term Results of Autologous Hematopoietic Cell Transplantation (AHCT) for Peripheral T Cell Lymphoma: The Stanford Experience.

Andy I. Chen, MD, PhD, Alex McMillan, PhD, Robert S. Negrin, MD, Sandra J. Horning, MD, Ginna G. Laport, MD

Blood (2007) 110 (11): 1906.

https://doi.org/10.1182/blood.V110.11.1906.1906

Published: 2007

Journal Articles

Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients

Bruce R. Blazar, Arlene H. Sharpe, Andy I. Chen, Angela Panoskaltsis-Mortari, Christopher Lees, Hisaya Akiba, Hideo Yagita, Nigel Killeen, Patricia A. Taylor

Blood (2003) 101 (9): 3741–3748.

https://doi.org/10.1182/blood-2002-10-3048

Published: 2003

NARROW

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Consolidative Autologous Stem Cell Transplant for Double Hit Lymphoma

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Extramedullary Multiple Myeloma Associated With Reduced Overall Survival: A Retrospective Single-Center Study

Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Prognostic Features, Treatments, and Disease-Specific Mortality Among Patients with Diffuse Large B-Cell Lymphoma Over the Age of 75: A Single-Center Retrospective Analysis

Outcomes of 252 Patients with High Risk Multiple Myeloma Treated with Hematopoietic Stem Cell Transplantation: Identification of Risk Factors Associated with Early Relapse, Shortened Progression Free and Overall Survival

A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

Improved Outcome with Busulfan, Melphalan, and Thiotepa Conditioning (BuMelTt) in Autologous Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

Long Term Results of Autologous Hematopoietic Cell Transplantation (AHCT) for Peripheral T Cell Lymphoma: The Stanford Experience.

Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only